Holen Sie sich die Stockscreener-App
0.3719
4.32%
-0.0168
Handel nachbörslich:
.39
0.0181
+4.87%
Schlusskurs vom Vortag:
$0.3887
Offen:
$0.39
24-Stunden-Volumen:
1.87M
Relative Volume:
0.14
Marktkapitalisierung:
$59.18M
Einnahmen:
$10.00M
Nettoeinkommen (Verlust:
$-29.47M
KGV:
-1.8595
EPS:
-0.2
Netto-Cashflow:
$-21.55M
1W Leistung:
-12.39%
1M Leistung:
-43.65%
6M Leistung:
-78.50%
1J Leistung:
-87.09%
1-Tages-Spanne:
$0.3719
$0.403
1-Wochen-Bereich:
$0.3551
$0.4373
52-Wochen-Spanne:
$0.20
$3.05
Mereo Biopharma Group Plc Adr Stock (MREO) Company Profile
Firmenname
Mereo Biopharma Group Plc Adr
Sektor
Branche
Telefon
4403330237300
Adresse
ONE CAVENDISH PLACE, LONDON
Compare MREO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MREO
Mereo Biopharma Group Plc Adr
|
0.3719 | 61.85M | 10.00M | -29.47M | -21.55M | -0.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Mereo Biopharma Group Plc Adr Stock (MREO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-30 | Herabstufung | Jefferies | Buy → Hold |
| 2025-03-27 | Eingeleitet | JP Morgan | Overweight |
| 2024-12-06 | Eingeleitet | Jefferies | Buy |
| 2024-06-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-10-13 | Fortgesetzt | BTIG Research | Buy |
| 2022-08-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-05-05 | Eingeleitet | BTIG Research | Buy |
| 2021-04-05 | Eingeleitet | Needham | Buy |
Alle ansehen
Mereo Biopharma Group Plc Adr Aktie (MREO) Neueste Nachrichten
Shareholders who lost money in shares of Mereo BioPharma Group PLC (NASDAQ: MREO) should contact Wolf Haldenstein immediately - Finviz
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – MREO - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming DeadlinesMREO - PR Newswire
Mereo BioPharma Group plc Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm Before April 6, 2026 to Discuss Your RightsMREO - ChartMill
MREO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Mereo (MREO) Investors of Securities Class Action Deadline on April 6, 2026 - Sahm
MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit - Barchart.com
MREO Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Mereo BioPharma Group plc - Sahm
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Mereo BioPharma - Chartmill
Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Mereo BioPharma Group plc Securities Class Action Lawsuit - Chartmill
Mereo BioPharma Group plcSponsored ADR (NASDAQ:MREO) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Given Average Recommendation of “Hold” by Brokerages - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Mereo BioPharma Group plc – MREO - Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plcMREO - ChartMill
MREO Stock Price, Forecast & Analysis | MEREO BIOPHARMA GROUP PL-ADR (NASDAQ:MREO) - Chartmill
Mereo BioPharma Group’s (MREO) “Buy” Rating Reiterated at BTIG Research - Defense World
A Look At Mereo BioPharma Group (MREO) Valuation After Mixed Setrusumab Phase 3 Results And Cash Runway Update - Sahm
MEREO BIOPHARMA (MREO) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Why Mereo BioPharma (MREO) Is Up 69.9% After Mixed Setrusumab Phase 3 Results And Pipeline Shift - Sahm
MREO: Setrusumab delivers robust BMD and pain improvements in OI, with key regulatory steps ahead - TradingView — Track All Markets
Mereo BioPharma Group (NASDAQ:MREO) Given New $3.00 Price Target at Needham & Company LLC - Defense World
MREO: Late-stage rare disease pipeline advances with strong data, strategic partnerships, and solid cash runway - TradingView — Track All Markets
Mereo BioPharma updates setrusumab program, extends cash runway - Investing.com
Mereo BioPharma updates setrusumab program, extends cash runway By Investing.com - Investing.com India
Mereo BioPharma Provides Corporate Update - Investing News Network
10 Stocks Under $1 That Will Explode - Insider Monkey
Mereo BioPharma Group Sees Unusually High Options Volume (NASDAQ:MREO) - Defense World
Mereo BioPharma Group Sees Unusually Large Options Volume (NASDAQ:MREO) - MarketBeat
RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint - Finviz
Jefferies downgrades Mereo BioPharma stock to Hold after setrusumab trial failure - Investing.com UK
Mereo BioPharma Group’s (MREO) Market Perform Rating Reaffirmed at Lifesci Capital - Defense World
Mereo BioPharma Group (NASDAQ:MREO) Given New $1.00 Price Target at BTIG Research - Defense World
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.51% - Investing.com UK
United States shares lower at close of trade; Dow Jones Industrial Average down 0.51% - Investing.com India
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.51% - Investing.com
Mereo BioPharma stock price target cut by BTIG to $1 from $6 - Investing.com South Africa
Baird lowers Mereo BioPharma stock price target to $1 from $8 after trial failures By Investing.com - Investing.com South Africa
Baird lowers Mereo BioPharma stock price target to $1 from $8 after trial failures - Investing.com UK
Ultragenyx stock plummets 43% after setrusumab fails in Phase III trial - Investing.com India
Silver Tumbles 8%; Society Pass Shares Spike Higher - Sahm
Dow Falls Over 100 Points; US Pending Home Sales Rise In November - Sahm
Mereo BioPharma stock plummets after failed Phase 3 trials By Investing.com - Investing.com South Africa
Mereo BioPharma stock plummets after failed Phase 3 trials - Investing.com India
Mereo BioPharma, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Mereo’s setrusumab fails primary endpoint in osteogenesis imperfecta trials By Investing.com - Investing.com India
Finanzdaten der Mereo Biopharma Group Plc Adr-Aktie (MREO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):